Factors Impacting the Prevalence of MDR Bacteria

NCT05100407 | Completed

• 1 other identifier: MDR and predictive factors
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

1. 1.To determine the prevalence of multidrug resistance bacteria in patient with different infections
2. 2.To evaluate patients' predictive risk factors of antimicrobial resistance
3. 3.To assess the association between patients' factors and prevalence of MDR bacteria

Conditions

Multi-antibiotic Resistance

Outcome Measures

Primary Outcomes (2)

• Prevalence of multidrug resistance bacteria in isolated patient specimen

  proportion of MDR bacteria that detected in isolated specimen

  based line value (zero months)

• Association of patient's factors with prevalence of multidrug resistance Bacteria.

  exploring the association between patient's factors and the prevalence of MDR bacteria by multivariate analysis

  based line value (zero months)

Secondary Outcomes (5)

• Prevalence of Methicillin resistance staph. Aureus (MERSA)

  based line value (zero months)

• Prevalence of vancomycin (-resistant Enterococci VRE)

  based line value (zero months)

• Prevalence of extended spectrum β lactamase producers (ESBL)

  based line value (zero months)

• Knowledge, attitude and practice (KAP) toward antibiotic use

  based line value (zero months)

• Risk factors for antibiotic resistance

  based line value (zero months)

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients hospitalized with bacterial infection and screened for MDR bacteria in AL-Zahraa teaching hospital or AL-Sader medical city

You may qualify if:

• patients who were screened for MDR bacteria
• patients who accepted to participate in the study

You may not qualify if:

• patients with no growth media
• patients who cannot communicated

Sponsors & Collaborators

• Kufa University: lead

Study Sites (1)

Faculty of pharmacy /kufa university

Najaf, Iraq

Location

Related Publications (7)

• Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309-18. doi: 10.1179/2047773215Y.0000000030. Epub 2015 Sep 7.

  PMID: 26343252 BACKGROUND

• Who.int. 2021. Antimicrobial resistance. [online] Available at: https://www.who.int/health-topics/antimicrobial-resistance

  BACKGROUND

• Bhardwaj, K., Shenoy M, S., Baliga, S., Unnikrishnan, B. and Baliga, B., 2021. Knowledge, attitude, and practices related to antibiotic use and resistance among the general public of coastal south Karnataka, India - A cross-sectional survey. Clinical Epidemiology and Global Health, 11, p.100717

  BACKGROUND

• Mallah N, Rodriguez-Cano R, Figueiras A, Takkouche B. Design, reliability and construct validity of a Knowledge, Attitude and Practice questionnaire on personal use of antibiotics in Spain. Sci Rep. 2020 Nov 26;10(1):20668. doi: 10.1038/s41598-020-77769-6.

  PMID: 33244041 BACKGROUND

• Marzan M, Islam DZ, Lugova H, Krishnapillai A, Haque M, Islam S. Knowledge, Attitudes, and Practices of Antimicrobial Uses and Resistance Among Public University Students in Bangladesh. Infect Drug Resist. 2021 Feb 11;14:519-533. doi: 10.2147/IDR.S289964. eCollection 2021.

  PMID: 33603416 BACKGROUND

• Rodriguez-Villodres A, Martin-Gandul C, Penalva G, Guisado-Gil AB, Crespo-Rivas JC, Pachon-Ibanez ME, Lepe JA, Cisneros JM. Prevalence and Risk Factors for Multidrug-Resistant Organisms Colonization in Long-Term Care Facilities Around the World: A Review. Antibiotics (Basel). 2021 Jun 7;10(6):680. doi: 10.3390/antibiotics10060680.

  PMID: 34200238 BACKGROUND

• Lim C, Takahashi E, Hongsuwan M, Wuthiekanun V, Thamlikitkul V, Hinjoy S, Day NP, Peacock SJ, Limmathurotsakul D. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. Elife. 2016 Sep 6;5:e18082. doi: 10.7554/eLife.18082.

  PMID: 27599374 BACKGROUND

Study Officials

• Hayder Asaad, assist. prof

  college of pharmacy kufa university

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: general pharmacist

Study Record Dates

• First Submitted: October 18, 2021
• First Posted: October 29, 2021
• Study Start: March 1, 2022
• Primary Completion: May 1, 2022
• Study Completion: May 15, 2022
• Last Updated: August 18, 2022

Record last verified: 2022-03

Locations

IR (1)